Crystal's Coder Hub🔬 CPT 11100 — Biopsy of Skin, Subcutaneous Tissue and/or Mucous Membrane; Single Lesion
Quick Reference
wRVU: 0.56 | Global Period: 000 (Same Day) | Assistant Payable: ❌ No | Bilateral Indicator: 3
📋 Clinical Description
CPT 11100 describes a biopsy of a single skin, subcutaneous tissue, or mucous membrane lesion, including simple closure when performed. The provider removes a tissue sample — by shave, punch, incisional, or excisional technique — for the purpose of histopathologic examination to establish, confirm, or rule out a diagnosis. The key differentiator between 11100 and an excision code is intent: a biopsy is performed to obtain a diagnostic tissue sample, whereas excision codes (113xx series) describe definitive removal of a lesion. If the provider excises a lesion completely with margins and the primary intent is removal rather than diagnosis, the appropriate excision code should be reported — not 11100.
Suspicious, undiagnosed, or diagnostically uncertain skin lesions are the primary indication for CPT 11100. This includes pigmented lesions concerning for melanoma, keratotic lesions suspicious for squamous cell carcinoma, atypical appearing nevi, oral mucosal lesions with malignant potential, and ulcerative or inflammatory lesions that have not responded to empiric treatment. When the clinical presentation is ambiguous and the provider requires tissue confirmation before proceeding with definitive treatment, 11100 is the appropriate code for the diagnostic step.
This procedure may be performed in the following clinical contexts:
- Pigmented Lesion — Rule Out Melanoma — Biopsy of an atypical or changing pigmented lesion to evaluate for melanoma; documentation should include ABCDE criteria or clinical concern; pathology report confirming the diagnosis will drive subsequent coding
- Keratotic or Hyperkeratotic Lesion — Rule Out SCC or BCC — Biopsy of a scaly, crusted, or indurated lesion suspicious for squamous or basal cell carcinoma; especially common in sun-damaged skin after actinic keratosis treatment failure
- Oral Mucosal Lesion — Biopsy for Histopathology — Biopsy of a suspicious oral, labial, or mucosal lesion (e.g., leukoplakia, erythroplakia, ulcer) to rule out dysplasia or carcinoma; the mucous membrane descriptor in 11100 covers these sites
- Inflammatory or Ulcerative Dermatosis — Diagnosis Confirmation — Biopsy to confirm a specific inflammatory condition (e.g., psoriasis, lichen planus, bullous pemphigoid) when the diagnosis is clinically uncertain or when systemic therapy is being considered
- Subcutaneous Lesion — Tissue Sampling — Sampling of a palpable subcutaneous nodule or mass when imaging or clinical exam is insufficient to establish a diagnosis and tissue is needed prior to definitive management planning
🔬 Anatomical & Procedural Considerations
| Technique Variant | Mechanism / Steps | Key Notes |
|---|---|---|
| Shave Biopsy | Tangential slicing of the lesion with a blade at or below the epidermal-dermal junction; no sutures typically required | Best for elevated, exophytic, or superficial lesions; not ideal for pigmented lesions suspicious for melanoma as it may transect the lesion and compromise Breslow depth measurement |
| Punch Biopsy | Circular cutting tool (2-8mm) rotated into dermis; specimen lifted and base transected with scissors | Most common technique; provides full-thickness dermis sample; simple closure with 1-2 sutures is included in 11100 |
| Incisional Biopsy | Sharp excision of a representative portion of a large lesion; includes deeper tissue sampling | Used for large lesions where complete excision is not performed; full-thickness sample with layered closure if needed — simple closure is included |
| Excisional Biopsy (Diagnostic Intent) | Complete removal of a small lesion with intent to obtain diagnostic tissue, not to achieve clean margins | When intent is diagnostic, 11100 is appropriate for small lesions completely removed for pathology; when intent is definitive removal with margins, use the appropriate 113xx excision code instead |
Clinical Pearl
The intent documented in the procedure note determines whether 11100 or an excision code is correct — not the technique or the completeness of removal. If the provider writes “excision of lesion for diagnostic purposes” or “shave biopsy submitted for pathology,” 11100 is appropriate. If the note reads “excision of lesion with 3mm margins to clear margins,” an excision code from the 113xx series is correct regardless of lesion size. Auditors look at the stated intent and the pathology report correlation — a biopsy followed immediately by a pathology report showing “lesion completely excised with clear margins” raises a flag for excision code review.
✅ Procedure Includes…
- Pre-procedure assessment of the lesion including clinical description and documentation of diagnostic uncertainty
- Local anesthesia (topical or injectable — bundled into 11100; not separately billable)
- Tissue sampling by shave, punch, incisional, or excisional technique
- Hemostasis (electrocautery, chemical, or pressure — included)
- Simple closure when performed (single-layer closure — included; if intermediate or complex closure is required, it may be separately reported)
- Specimen labeling, preparation, and submission to pathology
- Pathology interpretation is separately reported by the interpreting provider under the appropriate surgical pathology code (88302-88309)
❌ Excludes / Do Not Report Together
| Code | Description | Relationship to 11100 |
|---|---|---|
| 11101 | Biopsy of skin; each separate/additional lesion | Add-on code to 11100; report one unit of 11101 for each additional lesion biopsied beyond the first in the same session; do not report 11100 twice — use 11101 for lesion 2, 3, 4, etc. |
| 11300-11313 | Shave removal of epidermal or dermal lesion | Shave removal codes describe shave technique performed for removal (not diagnostic biopsy); when shave is performed to remove a benign lesion without intent for pathologic diagnosis, 113xx is correct — not 11100 |
| 11400-11646 | Excision, benign/malignant lesion | When the procedure is a definitive excision with margins, the 114xx-116xx excision family is correct; do not report 11100 when the intent is therapeutic removal with margins |
| 17000-17004 | Destruction of premalignant lesions | When actinic keratoses are destroyed (not biopsied), 17000/17003/17004 apply; 11100 is for tissue sampling, not destruction |
| E/M codes (992xx / 920xx) | Office visit, any level | Separately reportable only when modifier -25 is appended to the E/M code, documenting a significant, separately identifiable E/M service beyond the routine pre-procedure lesion assessment |
Bundling Alert — Global Period is 000, Not 010 or 090
CPT 11100 carries a 000 global period (same-day only). The global package includes same-day pre- and post-procedure services only — a follow-up visit the next day for wound check or suture removal is separately billable. The most commonly confused relationship is between 11100 and a same-day E/M visit: the pre-biopsy lesion assessment is bundled into the 11100 global. A separately identifiable E/M is only billable with modifier -25 on the E/M code when the provider performs a significant evaluation beyond the lesion assessment — for example, addressing a new dermatologic complaint or unrelated medical issue with distinct documentation. For unrelated conditions seen same day, modifier -24 applies to the E/M with documentation of the unrelated nature.
🌳 Code Tree — Surgery: Skin, Subcutaneous and Accessory Structures
CPT 11100-11101 Biopsy — Skin, Subcutaneous Tissue, Mucous Membrane
│
├── ▶▶ 11100 ◀◀ Biopsy of skin, subcutaneous tissue and/or mucous membrane;
│ single lesion ← YOU ARE HERE (Global: 000)
│
└── 11101 Each separate/additional lesion (add-on to 11100) (Global: ZZZ)
──────────────────────────────────────────────────────
Related Code Families for Context:
CPT 11300-11313 Shave Removal of Epidermal/Dermal Lesion
├── 11300 Shave removal, trunk/arms/legs; lesion diameter 0.5 cm or less
├── 11301 Lesion diameter 0.6-1.0 cm
├── 11302 Lesion diameter 1.1-2.0 cm
└── 11303 Lesion diameter over 2.0 cm
CPT 11400-11471 Excision, Benign Lesion
├── 11400 Excision, benign lesion; trunk/arms/legs; excised diameter 0.5 cm or less
└── [through 11471 by site and size]
CPT 11600-11646 Excision, Malignant Lesion
├── 11600 Excision, malignant lesion; trunk/arms/legs; excised diameter 0.5 cm or less
└── [through 11646 by site and size]
💰 RVU & Reimbursement Profile
| Component | Value |
|---|---|
| Work RVU (wRVU) | 0.56 (verify against current CMS MPFS for applicable year) |
| Global Period | 000 (Same Day) |
| Bilateral Indicator | 3 — Bilateral surgery concept does not apply; no bilateral reduction applied |
| Assistant Surgeon | ❌ Not payable |
| Co-Surgeon | ❌ Not applicable |
| Team Surgery | ❌ Not applicable |
| PC/TC Split | ❌ No — Procedure code only (Indicator 0) |
| Modifier -51 Exempt | No — subject to multiple procedure reduction rules |
| Anesthesia | Topical or local infiltration anesthesia — bundled into 11100; no separate anesthesia billing expected |
Bilateral Billing Rules
11100 has a bilateral indicator of 3, meaning the bilateral surgery concept does not apply — no bilateral reduction is triggered even when biopsies are performed on symmetric or bilateral sites. Each distinct lesion biopsied beyond the first is reported using the add-on code 11101, not as a bilateral line. There is no Medicare 150% bilateral reduction rule for this code. When billing multiple biopsies on the same date, the claim structure is: 11100 (first lesion) + 11101 × number of additional lesions.
🏷️ Modifier Reference
| Modifier | Name | When to Apply |
|---|---|---|
| -25 | Significant, Separately Identifiable E/M | Applied to the E/M code — not 11100 — when a separately identifiable office visit is performed on the same date; documentation must support a distinct, medically necessary evaluation beyond the pre-biopsy lesion assessment |
| -24 | Unrelated E/M During Postoperative Period | Applied to the E/M code when the patient is seen same day for a condition entirely unrelated to the biopsy; document the unrelated nature explicitly |
| -51 | Multiple Procedures | When 11100 is performed alongside other surgical procedures in the same session; apply to the lower-valued code; note that 11101 as an add-on is exempt from -51 |
| -52 | Reduced Services | Procedure partially completed (e.g., biopsy attempted but insufficient tissue obtained); document clinical reason |
| -53 | Discontinued Procedure | Procedure stopped after initiation due to patient safety concern; document reason thoroughly |
| -59 | Distinct Procedural Service | When 11100 is reported alongside another procedure that a payer inappropriately bundles; documents distinct lesion, anatomic site, or independent service |
| -XS | Separate Structure | Preferred X-modifier over -59 when billing 11100 for a lesion at an anatomically distinct site from another same-day procedure |
| -XU | Unusual Non-Overlapping Service | When a payer inappropriately bundles 11100 with another distinct service that clearly does not overlap |
🩺 Common ICD-10-CM Pairings
Premalignant and Uncertain Lesions
| ICD-10 Code | Description | HCC? | Clinical Notes |
|---|---|---|---|
| L57.0 | Actinic keratosis | ❌ No | Most common indication for skin biopsy in outpatient dermatology; document site and clinical concern; biopsy performed when diagnosis is uncertain or lesion is atypical |
| D48.5 | Neoplasm of uncertain behavior of skin | ❌ No | Use when the lesion has uncertain malignant potential and pathology is needed to classify; do not assume malignancy — let pathology drive final coding |
| D22.9 | Melanocytic nevi, unspecified | ❌ No | Atypical or changing nevi requiring biopsy; query for site specificity when documented |
| L98.9 | Disorder of skin and subcutaneous tissue, unspecified | ❌ No | Undiagnosed inflammatory or unclassified skin lesion; least specific — use only when no further clinical description is available; query provider when possible |
Benign Lesions Requiring Diagnostic Confirmation
| ICD-10 Code | Description | HCC? | Clinical Notes |
|---|---|---|---|
| L82.1 | Other seborrheic keratosis | ❌ No | Clinically atypical seborrheic keratosis; biopsy performed to confirm diagnosis and rule out malignancy |
| D23.9 | Other benign neoplasm of skin, unspecified | ❌ No | Clinically benign-appearing lesion requiring tissue confirmation; assign site-specific D23.- code when site is documented |
| B07.9 | Viral wart, unspecified | ❌ No | Atypical wart or verrucous lesion biopsied to confirm HPV-related etiology vs. other diagnosis |
| L85.8 | Other specified epidermal thickening | ❌ No | Hyperkeratotic lesion with uncertain diagnosis requiring histopathology |
Suspected or Confirmed Malignancy (Pre-Pathology)
| ICD-10 Code | Description | HCC? | Clinical Notes |
|---|---|---|---|
| D03.9 | Melanoma in situ, unspecified site | ✅ HCC 12 | Use after pathology confirms melanoma in situ; do not assign prior to pathology result — use D48.5 or the presenting symptom code at time of biopsy if diagnosis not yet confirmed |
| C44.91 | Unspecified malignant neoplasm of skin, unspecified | ✅ HCC 12 | Use only after pathology confirms malignancy; assign site-specific C44.- code when site is documented; do not assign at time of biopsy without pathology confirmation |
| Z12.83 | Encounter for screening for malignant neoplasm of skin | ❌ No | Use as the principal diagnosis when the biopsy is performed as part of a screening encounter in an asymptomatic patient; a screening code is not appropriate when a specific lesion with clinical concern drives the visit |
Mucous Membrane Lesions
| ICD-10 Code | Description | HCC? | Clinical Notes |
|---|---|---|---|
| K13.21 | Leukoplakia of oral mucosa, including tongue | ❌ No | White oral mucosal lesion with premalignant potential; biopsy to evaluate for dysplasia or carcinoma in situ |
| K13.79 | Other lesions of oral mucosa | ❌ No | Unclassified oral mucosal lesion requiring biopsy; use when more specific K13.- code is not supported by documentation |
| K12.39 | Other oral mucositis (ulcerative) | ❌ No | Persistent or atypical oral ulceration requiring histopathologic evaluation |
Coding Specificity Reminder
The most common specificity gap for 11100 ICD-10-CM pairings is assigning a confirmed malignancy code (C44.-, D03.-) before pathology results are available. At the time the biopsy is performed, the provider does not yet have a confirmed diagnosis — code to the presenting sign, symptom, or clinical finding (e.g., D48.5, L57.0, Z12.83) on the day of the biopsy. Once pathology is returned and the provider documents the confirmed diagnosis, the definitive code is assigned for subsequent visits. ICD-10-CM specificity requirements are not optional — the diagnosis code must reflect what is known at the time of the encounter, not what is later confirmed.
🏥 MS-DRG Considerations (Inpatient)
Inpatient Coding Reminder
CPT 11100 is performed exclusively in the outpatient or office setting. There are no routine MS-DRG assignments for this procedure — inpatient admission for a skin biopsy alone would not be supported by any payer, MAC, or utilization review body. If a patient undergoing an inpatient admission for an unrelated diagnosis also has a skin lesion biopsied, an ICD-10-PCS Excision code with a Diagnostic qualifier (X) is assigned for completeness, but it will have no meaningful impact on DRG grouping in isolation. See the ICD-10-PCS section below.
🔧 ICD-10-PCS Equivalents (Inpatient Facility Coding)
Note
Inpatient PCS coding for skin biopsy uses the Excision root operation (character B) with a Diagnostic qualifier (X) under Body System H (Skin and Breast). The qualifier X distinguishes a diagnostic biopsy from a therapeutic excision (qualifier Z = No Qualifier). PCS codes for skin biopsy are rarely encountered in the inpatient setting and will have minimal independent DRG impact; however, they should be assigned for coding accuracy when performed during an inpatient admission. The approach for skin procedures is External (X) in PCS, as skin is directly accessible without opening a body cavity.
| PCS Code | Full Description | Site |
|---|---|---|
0HB0XZX | Excision of Scalp Skin, External Approach, Diagnostic | Scalp lesion biopsy |
0HB1XZX | Excision of Face Skin, External Approach, Diagnostic | Facial lesion biopsy |
0HB4XZX | Excision of Neck Skin, External Approach, Diagnostic | Neck lesion biopsy |
0HB5XZX | Excision of Chest Skin, External Approach, Diagnostic | Chest/trunk lesion biopsy |
0HBAXZX | Excision of Right Lower Leg Skin, External Approach, Diagnostic | Right lower leg lesion biopsy |
0HBBXZX | Excision of Left Lower Leg Skin, External Approach, Diagnostic | Left lower leg lesion biopsy |
PCS Character Analysis — 0HB1XZX
| Position | Character | Value | Definition |
|---|---|---|---|
| 1 | Section | 0 | Medical and Surgical |
| 2 | Body System | H | Skin and Breast |
| 3 | Root Operation | B | Excision (cutting out or off, without replacement, a portion of a body part) |
| 4 | Body Part | 1 | Face Skin |
| 5 | Approach | X | External |
| 6 | Device | Z | No Device |
| 7 | Qualifier | X | Diagnostic |
PCS Qualifier: Diagnostic (X) vs. No Qualifier (Z)
- Use qualifier X (Diagnostic) when the intent of the skin excision is to obtain tissue for histopathologic examination — this is the inpatient PCS equivalent of CPT 11100
- Use qualifier Z (No Qualifier) when the excision is performed for therapeutic removal of the lesion — this is the PCS equivalent of a CPT excision code (114xx-116xx)
- The distinction between X and Z in PCS mirrors the CPT distinction between 11100 (biopsy/diagnostic intent) and the excision code family (therapeutic intent); the operative note’s stated purpose drives the qualifier selection
📝 Coding Examples
Example 1 — Office: Single Lesion Biopsy, Actinic Keratosis vs. SCC
Clinical Scenario: A 62-year-old male presents to dermatology for evaluation of a scaly, indurated lesion on the right forearm that has not responded to cryotherapy. The provider documents: “Lesion on right forearm, 0.8 cm, hyperkeratotic, firm, concerning for squamous cell carcinoma; punch biopsy performed under local anesthesia, specimen submitted for pathology; simple closure with one interrupted suture; pathology results pending.” No separate E/M is documented beyond the lesion assessment.
| Field | Code | Rationale |
|---|---|---|
| CPT | 11100 | Single skin biopsy; punch technique; simple closure included; intent is diagnostic — pathology pending |
| PDx | L57.0 | Actinic keratosis — most specific diagnosis supported at time of biopsy; do not assign C44.- until pathology confirms malignancy |
Note
No modifier -25 applies — no separately identifiable E/M beyond the lesion assessment is documented. Once the pathology report is returned and reviewed at a subsequent visit, the confirmed diagnosis (e.g., SCC in situ, invasive SCC) is assigned on that encounter. Do not retroactively change the biopsy date diagnosis code.
Example 2 — Office: Multiple Biopsies Same Session with Separate E/M
Clinical Scenario: A 55-year-old female presents for a full-body skin check. The provider performs a complete skin examination and identifies three suspicious lesions: one on the left shoulder (pigmented, changing), one on the left forearm (hyperkeratotic, indurated), and one on the back (raised, pearly). A separately documented E/M note addresses new onset pruritus with distinct history, physical examination, and MDM beyond lesion assessment. All three lesions are biopsied by punch technique with simple closure. Local anesthesia administered for each site.
| Field | Code | Rationale |
|---|---|---|
| CPT 1 | 99213--25 | Separately identifiable E/M for new pruritus complaint — modifier -25 on the E/M code; documentation supports a distinct evaluation with history, exam, and MDM beyond lesion biopsy assessment |
| CPT 2 | 11100 | First lesion biopsied (left shoulder pigmented lesion) |
| CPT 3 | 11101 | Second additional lesion biopsied (left forearm hyperkeratotic lesion) — add-on to 11100 |
| CPT 4 | 11101 | Third additional lesion biopsied (back pearly lesion) — second unit of add-on 11101 |
| PDx | D48.5 | Neoplasm of uncertain behavior of skin — most appropriate pre-pathology code for suspicious lesions with malignant potential |
| SDx | L29.9 | Pruritus, unspecified — supports the separately identifiable E/M |
Warning
Modifier -25 belongs on the E/M code only — never on 11100 or 11101. The E/M documentation must clearly stand as a separately identifiable service with its own history, physical, and medical decision-making beyond the pre-biopsy lesion assessment. Additionally, 11101 is an add-on code — it is never reported alone without 11100 as the primary code on the same claim, and it is not subject to modifier -51 (add-on codes are inherently exempt from multiple procedure reduction).
Example 3 — Office: Oral Mucosal Biopsy, CDI Query Scenario
Clinical Scenario: A 48-year-old male tobacco user presents to his primary care provider with a persistent white oral mucosal lesion on the left buccal mucosa present for approximately 6 weeks. The provider documents “white patch, left buccal mucosa, non-tender, non-removable with gauze; biopsy performed with punch technique, specimen submitted to pathology for evaluation of dysplasia or carcinoma; simple closure; tobacco use documented.” The coder notes the documentation does not specify whether the provider considers this leukoplakia, dysplasia, or other diagnosis.
| Field | Code | Rationale |
|---|---|---|
| CPT | 11100 | Single mucous membrane biopsy; punch technique; simple closure included; mucous membrane is explicitly covered under 11100 descriptor |
| PDx | K13.21 | Leukoplakia of oral mucosa — clinically supported by “white patch, non-removable” description; direct documentation supports this code without a provider query |
| SDx | F17.210 | Nicotine dependence, cigarettes, uncomplicated — tobacco use is a significant risk factor for oral malignancy and supports medical necessity; document and code when noted |
Note
Global period reminder: 11100 has a 000 global period. The pathology interpretation is a separately billable service reported by the interpreting pathologist under surgical pathology codes (88302-88309) — this is not bundled into 11100. The biopsy (11100) and the pathology interpretation are two distinct services by two different providers or departments; both are separately payable on the same date or different dates.
⚠️ Common Coding Pitfalls
-
Assigning a Confirmed Malignancy Code Before Pathology is Available: At the time of biopsy, the diagnosis is uncertain by definition — that is why the biopsy is being performed. Assigning C44.- or D03.- codes on the biopsy date without pathology confirmation is a diagnosis coding violation. Code to the presenting clinical finding (D48.5, L57.0, the lesion descriptor) on the day of the biopsy and assign the confirmed diagnosis at the follow-up visit when pathology results are reviewed and documented by the provider.
-
Reporting 11100 Instead of an Excision Code When Intent is Therapeutic: When the provider’s documented intent is to remove a lesion completely with margins — not simply to sample it for diagnosis — the appropriate code is from the 114xx (benign) or 116xx (malignant) excision series, not 11100. Using 11100 for a definitive excision constitutes undercoding and misrepresents the service performed. Read the intent statement in the procedure note before assigning the code.
-
Forgetting to Report 11101 for Additional Lesions: CPT 11100 covers only the first lesion biopsied. Each additional lesion biopsied in the same session requires one unit of add-on code 11101. Failing to report 11101 for lesions 2, 3, and 4 leaves legitimate reimbursement on the table. The procedure note must document each lesion separately with its own site description to support each unit of 11101.
-
Placing Modifier -25 on the Procedure Code Instead of the E/M: Modifier -25 must be appended to the E/M service code, not to CPT 11100. This is one of the most common billing errors in dermatology and primary care wound audits. The E/M documentation must independently support a significant, separately identifiable evaluation — the pre-biopsy lesion assessment alone does not meet this standard and is bundled into 11100.
-
Separately Billing Local Anesthesia: Local anesthetic injection or topical anesthesia used for the biopsy is bundled into CPT 11100 and is not separately reportable. Appending a local anesthesia injection code on the same claim as 11100 for the same lesion is an NCCI bundling violation.
-
Billing 11100 for Lesion Destruction Instead of Biopsy: When a provider destroys a lesion (cryotherapy, electrodesiccation, laser) without submitting tissue for pathology, this is a destruction procedure — not a biopsy. CPT 17000-17286 or other destruction codes apply. CPT 11100 requires that tissue be removed and submitted for histopathologic examination; if no specimen is sent to pathology, 11100 is not supported.
📎 Sources
1. AMA CPT 2025 Professional Edition — Code 11100-11101, Biopsy of Skin, Subcutaneous Tissue and/or Mucous Membrane · 2. CMS 2025 Medicare Physician Fee Schedule Final Rule (CMS-1807-F) — RVU and Global Period Assignments · 3. CMS RVU25A Relative Value Files — Work RVU: 0.56, Global Period: 000, Bilateral Indicator: 3 · 4. NCCI Policy Manual Chapter 1 & Chapter 4 (Integumentary System), CMS 2024-2025 — Biopsy Bundling Rules and Mutually Exclusive Code Edits · 5. ICD-10-CM Official Guidelines for Coding and Reporting FY2025 — Section I.C.2 (Neoplasms), Section I.C.12 (Skin and Subcutaneous Tissue), Section IV.H (Uncertain Diagnosis — Outpatient) · 6. ICD-10-PCS Official Guidelines for Coding and Reporting FY2025 — Root Operation Excision (B), Qualifier X (Diagnostic), Body System H (Skin and Breast) · 7. AAPC Dermatology Coding Guidelines — CPT 11100 vs. Excision Intent Distinction · 8. CMS Medicare Coverage Database — Billing and Coding: Skin Biopsy and Lesion Removal · 9. Palmetto GBA Jurisdiction M — Skin Biopsy and Lesion Removal Policy · 10. ICD-10-CM FY2025 Tabular List — Chapter 2 (Neoplasms), Chapter 12 (Skin), Chapter 11 (Digestive — K13 Oral Mucosa)